Mandate

Vinge advises EQT in connection with sale of care giant Aleris

July 02, 2010

EQT III has entered into an agreement to sell the Aleris healthcare group to Investor AB. The transaction value is SEK 4.4 billion with a supplementary purchase price of up to SEK 100 million. The transaction is subject to approval by the relevant competition authorities.

The Vinge team advising EQT consisted of Tuula Tallavaara, David Andersson, Johan Mattsson and Ulrich Ziche. Peter Alstergren provided competition law advice and Carl Gustav De Geer was the responsible partner.

Aleris has approximately 5000 employees and has operations in Sweden, Norway and Denmark. Aleris’ turnover in 2009 was approximately SEK 4 billion.

Related

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026

Vinge has advised Skeptiva AB in connection with its financing round

Skeptiva is developing the next generation of cybersecurity defenses against fraud. The company has developed an AI application that detects attacks and alerts users in real time.
March 11, 2026

Vinge has advised Main Capital in connection with the acquisition of Good Solutions Sweden AB

Good Solutions Sweden AB (”Good Solutions”) provides software that helps factories identify and reduce production losses. The software converts data from machines and operators into insights that can be used to streamline production and increase profitability.
March 11, 2026